TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19730274

Group type: EXPERIMENTAL
Intervention: Specialized psychotherapy for suicide attempting adolescents (n = 17)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Medication algorithm (n = 14)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and medication (n = 93)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 124
Study: 16769264

Group type: EXPERIMENTAL
Intervention: Daily oral 30 mg risedronate, oral 1000 mg elemental calcium, and oral 400 IU cholecalciferol
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Slowly titrated anti-resorptive therapy (subcutaneous calcitonin followed by titrated doses of risedronate)
Number of subjects: 1
Study: 15333854

Group type: EXPERIMENTAL
Intervention: midazolam and 5 mg i.v. hydrocodone
Number of subjects: 120

Group type: COMPARATOR
Intervention: midazolam and placebo
Number of subjects: 120
Study: 11761205

Group type: EXPERIMENTAL
Intervention: Education of practice teams about the management of depression
Number of subjects: 0
Study: 9425363

Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (ABD; 1 mg/kg.day on days 1‐20, 21‐40 and 61‐80)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sodium antimony gluconate (SAG; 20 mg/kg day for 20-day courses with 20-day drug-free intervals)
Number of subjects: 11
Study: 8256454

Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anabolic steroid therapy
Number of subjects: 0
Study: 3541613

Group type: EXPERIMENTAL
Intervention: Ritodrine plus adjunctive magnesium sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritodrine plus placebo
Number of subjects: 0
Study: 31665939

Group type: EXPERIMENTAL
Intervention: vaginal suppository progesterone
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: tablet aspirin 80 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: control group without any intervention
Number of subjects: 140
Study: 31848889

Group type: EXPERIMENTAL
Intervention: Acupuncture plus Early Enteral Nutrition (EEN)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acupuncture plus Conventional
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early Enteral Nutrition (EEN)
Number of subjects: 200
Study: 28949056

Group type: EXPERIMENTAL
Intervention: Exercise tolerance testing (ETT) in RAND-CFR patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (n=9) without diabetes
Number of subjects: 20
Study: 27777094

Group type: EXPERIMENTAL
Intervention: NO3‐rich beetroot juice (BR; 70 mL·day‐1; 6.4 mmol of NO3‐)
Number of subjects: 36
Study: 24615411

Group type: EXPERIMENTAL
Intervention: Enhanced expression of competence
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Enhanced expression of honesty
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Enhanced expression of caring
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Communication of honesty and caring
Number of subjects: 345
Study: 23289279

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy for 10 days during cast immobilization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PEMF therapy)
Number of subjects: 60
Study: 20946748

Group type: EXPERIMENTAL
Intervention: Perceived approval of close friends
Number of subjects: 3753

Group type: EXPERIMENTAL
Intervention: Perceived approval of typical students
Number of subjects: 3753

Group type: EXPERIMENTAL
Intervention: Parental approval
Number of subjects: 3753
Study: 18675396

Group type: EXPERIMENTAL
Intervention: 10-week device-supported isolated lumbar extension training, twice a week
Number of subjects: 129

Group type: COMPARATOR
Intervention: Regular physical therapy mainly consisting of exercise therapy and aerobic activities
Number of subjects: 129
Study: 15726102

Group type: EXPERIMENTAL
Intervention: Annual mammography screening from age 40 to 41
Number of subjects: 160921

Group type: COMPARATOR
Intervention: 3-yearly UK national programme invitation at age 50-52
Number of subjects: 160921
Study: 12854090

Group type: EXPERIMENTAL
Intervention: HPV-16 L1 VLP vaccine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 10596514

Group type: EXPERIMENTAL
Intervention: Cognitive coping skills training added to operant-behavioral treatment (OPCO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operant program + group discussion (OPDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control (WLC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less protocolized operant program (OPUS)
Number of subjects: 0
Study: 8692556

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ondansetron plus dexamethasone
Number of subjects: 0
Study: 1725444

Group type: EXPERIMENTAL
Intervention: 4 mg lacidipine with 160 mg propranolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 160 mg propranolol with 4 mg lacidipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 4 mg lacidipine alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: 160 mg propranolol alone
Number of subjects: 24
Study: 6617712

Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg single dose)
Number of subjects: 32
Study: 30857862

Group type: EXPERIMENTAL
Intervention: Bilateral Superficial Cervical Plexus Block (BSCPB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Local Wound Infiltration (LWI)
Number of subjects: 70
Study: 28177460

Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: lapatinib
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: lapatinib + trastuzumab
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: trastuzumab alone
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: lapatinib added to trastuzumab
Number of subjects: 203
Study: 26098027

Group type: EXPERIMENTAL
Intervention: EMA‐EMI condition (Ecological Momentary Intervention with text messages promoting moderation)
Number of subjects: 130

Group type: COMPARATOR
Intervention: EMA condition (Ecological Momentary Assessment)
Number of subjects: 130
Study: 24289736

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study: 21332627

Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg once daily
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 19095839

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (RM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no RM)
Number of subjects: 0
Study: 17761914

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy (NBO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air (Control)
Number of subjects: 0
Study: 14600537

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 0
Study: 11022983

Group type: EXPERIMENTAL
Intervention: 2 g intravenous MgSO4
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 34
Study: 9104904

Group type: EXPERIMENTAL
Intervention: Oral propafenone (mean dose 663 +/- 99 mg/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Oral sotalol (mean dose 200 +/- 57 mg/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of intolerable side effects
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of tolerable side effects
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of attack frequency at baseline
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of attack frequency after treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of effective response to drugs
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of decrease of symptom scores
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison of percentage decrease of ventricular rate during AF
Number of subjects: 79
Study: 1436603

Group type: EXPERIMENTAL
Intervention: 100 mg heparan sulfate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 mg heparan sulfate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2947099

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicergoline (standard alpha blocker)
Number of subjects: 0
Study: 29751254

Group type: EXPERIMENTAL
Intervention: Isometric pre-conditioning (IPC) with 10 maximal voluntary isometric contractions (MVIC) in a leg press machine two days prior to downhill running
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no IPC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isometric pre-conditioning (IPC)
Number of subjects: 30
Study: 26634419

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 81 mg daily with 50 mg losartan
Number of subjects: 28

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 81 mg every 3 days with 50 mg losartan
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 28
Study: 25431866

Group type: COMPARATOR
Intervention: iAMP21 cases (n=14) in the MRD low-risk group
Number of subjects: 46

Group type: COMPARATOR
Intervention: iAMP21 cases (n=27) in the MRD intermediate-risk group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-iAMP21 patients
Number of subjects: 46
Study: 22607698

Group type: EXPERIMENTAL
Intervention: Care pathway for PFF or COPD containing three active components: formative evaluation of team performance, evidence-based key interventions, training in care pathway development.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Care pathway for PFF or COPD.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 132
Study: 20413513

Group type: EXPERIMENTAL
Intervention: INCB13739 200 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 18317667

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 40
Study: 16037732

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural morphine 2 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% paraspinal muscle infiltration (30 mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline paraspinal muscle infiltration (30 mL)
Number of subjects: 80
Study: 12512988

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush (experimental toothbrush)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Colgate Actibrush (control toothbrush)
Number of subjects: 39
Study: 10661525

Group type: EXPERIMENTAL
Intervention: Prototype 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prototype 2 with wrist splint
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Platform Cane (PC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard Cane (SC)
Number of subjects: 10
Study: 8752794

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adenosine stress echocardiography
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stress echocardiography (both dobutamine and adenosine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ST segment depression (≥ 1mm) during dobutamine test
Number of subjects: 120
Study: 2014968

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 22
Study: 7138270

Group type: EXPERIMENTAL
Intervention: Air pressure splint treatment for 5 consecutive days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control hand (no treatment)
Number of subjects: 30
Study: 31385663

Group type: EXPERIMENTAL
Intervention: Severe co-morbidity (CIRS-G score grades 3 and 4)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Severe heart disease
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: CIRS-G score
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Skeletal Muscle Index (SMI)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 436
Study: 27615562

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg and ezetimibe 10mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine statin therapy
Number of subjects: 61
Study: 26540594

Group type: EXPERIMENTAL
Intervention: Stratafix bidirectional barbed suture
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional suture
Number of subjects: 47
Study: 25365686

Group type: EXPERIMENTAL
Intervention: Tailored communication interventions via interactive voice response (IVR) call, graded segments for outreach.
Number of subjects: 46697

Group type: COMPARATOR
Intervention: Control group receiving no communication.
Number of subjects: 46697
Study: 22288661

Group type: EXPERIMENTAL
Intervention: High soft drink consumers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interdependence-primed participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asian-Americans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High soft drink consumers (Chinese)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low soft drink consumers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independence-primed participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: European-North Americans
Number of subjects: 0
Study: 19104182

Group type: EXPERIMENTAL
Intervention: Automated regular bolus of 0.125% levobupivacaine (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous infusion of 0.125% levobupivacaine (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (Automated bolus and Continuous infusion)
Number of subjects: 50
Study: 17983296

Group type: EXPERIMENTAL
Intervention: Happy emotional state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sad emotional state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral affect control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High elaboration conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low motivation to think
Number of subjects: 0
Study: 16027401

Group type: EXPERIMENTAL
Intervention: ABT‐578 (200, 400, or 800 microg) as daily intravenous infusions for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12381339

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched TPN (0.3 g/kg L-alanine-L-glutamine)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard TPN (1.5 g/kg body weight protein)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched TPN
Number of subjects: 28
Study: 9619493

Group type: EXPERIMENTAL
Intervention: Intravenous t-PA (tissue plasminogen activator) at a dose of 0.9 mg/kg, administered within 3 hours of symptom onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin, heparin, and low‐molecular‐weight heparin products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic agents
Number of subjects: 0
Study: 8110571

Group type: EXPERIMENTAL
Intervention: Tape-recorded lists of 10 neutral words presented during anaesthesia.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Blank tape (control group).
Number of subjects: 48
Study: 2540373

Group type: EXPERIMENTAL
Intervention: KHCO3, 60 mmol/day for 12 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: NaHCO3, 60 mmol/day for 12 days
Number of subjects: 10
Study: 6997743

Group type: EXPERIMENTAL
Intervention: Bovine lung heparin
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intestinal-mucosa A heparin
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intestinal-mucosa O heparin
Number of subjects: 149

Group type: COMPARATOR
Intervention: Combined intestinal-mucosa A and O
Number of subjects: 149
Study: 29800420

Group type: EXPERIMENTAL
Intervention: Automated Telephone Follow-up (ATF)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 440
Study: 28145739

Group type: EXPERIMENTAL
Intervention: Seated heel raising and lowering
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bilateral standing heel raising and lowering
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bilateral heel raising and unilateral lowering
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Unilateral heel raising and lowering
Number of subjects: 21
Study: 25237150

Group type: EXPERIMENTAL
Intervention: Peaceful Buddhist music video (MV) intervention for 30 minutes before bedtime
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual-care control condition
Number of subjects: 38
Study: 24054431

Group type: EXPERIMENTAL
Intervention: Oral propranolol (0.25 or 0.5 mg/kg/6 hours) added to standard treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 52
Study: 21252728

Group type: EXPERIMENTAL
Intervention: 10 mg of equol supplement per day
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 20037095

Group type: EXPERIMENTAL
Intervention: Endoscopic radial artery harvesting (ERAH) with the VasoView system (Boston Scientific)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional open technique for radial artery harvesting
Number of subjects: 50
Study: 17766528

Group type: EXPERIMENTAL
Intervention: Intervention group (provider training, psychosocial screening tool, access to resource book)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 200
Study: 17409978

Group type: EXPERIMENTAL
Intervention: Selective mediastinoscopy
Number of subjects: 566

Group type: COMPARATOR
Intervention: Routine mediastinoscopy
Number of subjects: 566
Study: 14612326

Group type: EXPERIMENTAL
Intervention: 200 messages generated by 20 female speakers in five elocution styles
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 200 messages evaluated according to 20 criteria extracted from the first experiment
Number of subjects: 200
Study: 10489653

Group type: EXPERIMENTAL
Intervention: Attendance at a memory clinic
Number of subjects: 50
Study: 9156885

Group type: EXPERIMENTAL
Intervention: Mechanical Plant (M.P. group 1)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Design Office (D.O. Group II)
Number of subjects: 264
Study: 1743329

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) cotreatment
Number of subjects: 25
Study: 7134840

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 99mTc-DIDA cholescintigraphy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Infusion tomography
Number of subjects: 45
Study: 31657614

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 50
Study: 30285672

Group type: EXPERIMENTAL
Intervention: Transdiagnostic group CBT (tCBT) - 12 weekly 2-hour group sessions following a manualized treatment protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) for anxiety disorders
Number of subjects: 0
Study: 26822537

Group type: EXPERIMENTAL
Intervention: Self-management cues + incentive (free dental treatment)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study: 24439713

Group type: EXPERIMENTAL
Intervention: Topical anesthetic putty
Number of subjects: 110

Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 110
Study: 22341824

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including strengthened STI syndromic management, mobile-team outreach for STI screening, presumptive treatment for trichomoniasis, and condom promotion.
Number of subjects: 15261

Group type: COMPARATOR
Intervention: Control group receiving standard care.
Number of subjects: 15261

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention specifically for young adult women and FSWs.
Number of subjects: 15261
Study: 21098443

Group type: EXPERIMENTAL
Intervention: Myocardial infarction (MI)
Number of subjects: 190915
Study: 18670365

Group type: EXPERIMENTAL
Intervention: Combination therapy of low-dose simvastatin 10 mg with ezetimibe 10 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: High-dose simvastatin 80 mg
Number of subjects: 19
Study: 16002796

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid/d for 3 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 41
Study: 12450886

Group type: EXPERIMENTAL
Intervention: High saturated fatty acids diet (total fat, 36% of energy; SFAs, 18% of energy; MUFAs, 10% of energy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Monounsaturated fatty acids diet (total fat, 35% of energy; SFAs, 9% of energy; MUFAs, 19% of energy)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids supplementation (3.6 g n-3 fatty acids/d; 2.4 g eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10605601

Group type: EXPERIMENTAL
Intervention: Topical application of salicylic acid in ethanol solution
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oral administration of 2 g acetylsalicylic acid
Number of subjects: 2
Study: 8557785

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) dosage of 22.8 +/- 10.3 mg/kg/day
Number of subjects: 32
Study: 1954079

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg plus Triamterene 50 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terbutaline alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg plus Terbutaline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg plus Triamterene 50 mg plus Terbutaline
Number of subjects: 15
Study: 6751166

Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg daily for 24 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo-control period
Number of subjects: 22
Study: 31996192

Group type: EXPERIMENTAL
Intervention: ST + Sn (screen-time and unhealthy snacking)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ST (screen-time only)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sn (unhealthy snacking only)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Parents in ST + Sn and ST groups
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75